drugset / Trial / NCT06651866
Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients
NaSingle-groupOpen-labelTreatment
Summary
to observe the dose-limiting toxicity (DLT) of liposomal mitoxantrone hydrochloride injection combined with cytarabine and decitabine in the initial treatment of acute myeloid leukemia (AML), to explore the maximum tolerated dose (MTD) of the combined D-CMG regimen, and to evaluate its safety and efficacy
Timeline
- Start
- 2024-12-12
- Primary completion
- 2026-12-31
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitoxantrone | Small molecule | 12 mg/m2 | Intravenous |
| Subject | Mitoxantrone | Small molecule | 18 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | 10 mg/m2 | Intravenous |
| Background | Decitabine | Small molecule | 25 mg | Intravenous |